| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5747472 | SANDOZ | Therapeutic methods for using ARA-G derivatives |
Feb, 2013
(11 years ago) | |
| US5492897 | SANDOZ | Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives |
Feb, 2013
(11 years ago) | |
| US5821236 | SANDOZ | Tumor treatment with arabinofuranosyl purine derivatives |
Feb, 2013
(11 years ago) | |
| US5424295 | SANDOZ | 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine |
Jun, 2017
(6 years ago) | |
Arranon is owned by Sandoz.
Arranon contains Nelarabine.
Arranon has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Arranon are:
- US5747472
- US5492897
- US5821236
- US5424295
Arranon was authorised for market use on 28 October, 2005.
Arranon is available in injectable;intravenous dosage forms.
Arranon can be used as treatment of patients with t-cell acute lymphoblastic leukemia whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens, treatment of patients with t-cell acute lymphoblastic leukemia and t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens, treatment of patients with t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
The generics of Arranon are possible to be released after 13 June, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 28, 2012 |
Drugs and Companies using NELARABINE ingredient
Market Authorisation Date: 28 October, 2005
Treatment: Treatment of patients with t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens; Treatment of patients with t-ce...
Dosage: INJECTABLE;INTRAVENOUS
ARRANON family patents
